Develops innovative treatments for various types of cancer. Focuses on a pipeline of antibodies designed to target specific cancer cells. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Growth: Sales growth trails the sector average.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $5.4M against $0 in annual sales.
The stock sits at $0.54. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At last year’s rate of cash burn, the cash lasts about 1.3 years. After that, the company needs to find new money.
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
The takeaway: KAPA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.